Who Should Not Take Mounjaro (Tirzepatide)
Mounjaro is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and should not be used during pregnancy or breastfeeding. 1, 2
Absolute Contraindications
Thyroid Cancer Risk
- Do not use in individuals with a personal or family history of medullary thyroid carcinoma 3, 1
- Do not use in patients with multiple endocrine neoplasia type 2 1, 2
- Black-box warning exists due to thyroid C-cell tumor findings in rodent studies, though human relevance remains uncertain 1
Pregnancy and Breastfeeding
- Pregnancy is an absolute contraindication as safety has not been established 2
- Breastfeeding is contraindicated due to lack of safety data 2
Conditions Requiring Extreme Caution or Avoidance
Gastrointestinal Disorders
- Not recommended in patients with clinically meaningful gastroparesis, as tirzepatide delays gastric emptying and will worsen existing symptoms 2
- Use with extreme caution in patients with prior pancreatitis, as acute pancreatitis has been reported in clinical trials 1, 2
- Severe constipation and small-bowel obstruction/ileus have been documented 3, 1
Renal Disease
- Use caution when initiating or escalating doses in patients with kidney disease due to increased risk of acute kidney injury from dehydration secondary to gastrointestinal side effects 3, 1, 2
- While no dose adjustment is required for mild-to-moderate renal impairment, careful monitoring is essential 1
Important Clinical Precautions
Gallbladder Disease
- May cause cholelithiasis and gallstone-related complications 1, 2
- Monitor throughout treatment for right-upper-quadrant pain, fever, or other signs of biliary disease 1
Hypoglycemia Risk with Concomitant Medications
- Dose reduction required when combined with insulin or sulfonylureas to minimize hypoglycemia risk 1, 2
- When used as monotherapy, tirzepatide carries low intrinsic hypoglycemia risk due to its glucose-dependent mechanism 1
Drug Interactions
- Delays gastric emptying, affecting absorption of oral medications 1, 2
- Close monitoring required for medications with narrow therapeutic indices (e.g., warfarin) 1, 2
- For oral hormonal contraceptive users, advise non-oral contraception or addition of barrier method for 4 weeks after initiation and each dose escalation 3, 1, 2
Genetic Considerations
- Screening for G6PD deficiency is important when considering GLP-1 class medications, particularly in patients of African American, Mediterranean, or Southeast Asian descent 2
Common Pitfalls to Avoid
- Do not ignore dosing errors: Real-world data shows incorrect dose administration is the most common adverse event, increasing 8-fold from 2022 to 2024 4
- Discontinue immediately if pancreatitis is suspected—do not continue while investigating 1, 2
- Do not overlook dehydration risk: Gastrointestinal side effects can lead to severe electrolyte disturbances, including documented cases of ventricular fibrillation 1
- Stop before elective procedures: The 5-day half-life and delayed gastric emptying increase aspiration risk during anesthesia 1